Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Incretinomimetics and inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. Previous retrospective studies have shown that these treatments induced an increase in pancreatic mass with potentially a risk for pancreatitis and development of precancerous lesions.

The aim of our study is to provide a better understanding of the pathophysiological mechanisms of increased volume and / or pancreatic exocrine secretion when exposed to certain treatment of type 2 diabetes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erasme University Hospital
• Treatments: Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Liraglutide; Lixisenatide

Criteria

Inclusion Criteria:

• Type 2 diabetes inadequately controlled or intolerant to metformin

• Obtaining informed consent

• Aged between 18 and 70 years

• BMI between 20 and 45 kg / m²

Exclusion Criteria:

• Contraindication to nuclear magnetic resonance (NMR):

• Carrying a metallic foreign body (pacemaker, valve, intraocular equipment, clips)

• Allergy to Gadolinium / Secretin

• Pregnancy or breastfeeding

• Contraindication to treatment with incretinomimetic:

• Hypersensitivity to the active substance or to any of the excipients

• Severe Gastroparesis

• Severe renal impairment

• History of Surgery (gastroduodenal, pancreatic or ileocecal)

• Presence or history of pancreatic disease

• Active alcoholism